Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering-Plough

This article was originally published in The Tan Sheet

Executive Summary

HealthCare Products division revenues increase 2% to $162 mil. in the third quarter, led by "higher sales" of foot care products, the firm reports Oct. 21. Schering markets the Dr. Scholl line of foot remedies. Nine-month sales jumped 9% to $582 mil. due to increased sales of sun care (Coppertone) and foot care products. A 42% boost in Claritin antihistamine sales helped the firm's net revenues rise 16% to $2 bil. in the quarter; net earnings grew 21% to $432 mil. in the three-month period
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS089007

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel